Brief: Spexis, SGI Announce Plans For Clinical Trial Partnership

Spexis AG

08/02/2023 06:23

Feb 8 (Reuters) - Spexis Ag  SPEXN.S :
    * SPEXIS AND SPRIM GLOBAL INVESTMENTS (SGI) ANNOUNCE PLANS
FOR
CLINICAL TRIAL PARTNERSHIP TO FUND UP TO HALF OF THE PROJECTED
PHASE 3 CLINICAL DEVELOPMENT COSTS OF COLIFIN®
    * PARTNERSHIP, WHICH INCLUDES A DEBT FACILITY, IS EXPECTED
TO
PROVIDE SPEXIS WITH UP TO HALF OF PHASE 3 CLINICAL DEVELOPMENT
COSTS OF COLIFIN
    * AND ENABLE INITIATION OF SPEXIS' PHASE 3 COPILOT STUDY,
EXPECTED
IN Q2 OF 2023
    * MAJORITY OF SUCH FUNDING IS PLANNED TO BE IN FORM OF
SENIOR DEBT
TIED TO FUNDING OF COPILOT AND COPA STUDIES

Further company coverage:  SPEXN.S 
 (Reporting by Berlin Newsroom)
 ((berlin.newsroom@thomsonreuters.com;))